PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency

Biochem Biophys Res Commun. 2004 Apr 23;317(1):205-10. doi: 10.1016/j.bbrc.2004.03.031.

Abstract

Approximately 4% of the Japanese population genetically lack plasma platelet activating factor acetylhydrolase (PAF-AH) and show a higher prevalence of thromboembolic disease, but whether they are susceptible to another PAF-related disease, asthma, remains controversial. To determine the role of plasma PAF-AH in airway physiology, we performed PAF bronchoprovocation tests in 8 plasma PAF-AH-deficient subjects and 16 control subjects. Serial inhalation of PAF (1-1000 microg/ml) concentration-dependently induced acute bronchoconstriction, but there was no significant difference between PAF-AH-deficient and control subjects (11.7 +/- 4.6% vs. 9.6 +/- 2.8% decrease in forced expiratory volume in 1 s). Transient neutropenia after single inhalation of PAF (1000 microg/ml) showed no significant difference between the groups either in its magnitude (72 +/- 11% vs. 65 +/- 9% decrease) or duration (4.1 +/- 1.0 vs. 3.3 +/- 0.8 min). In conclusion, a lack of plasma PAF-AH activity alone does not augment physiological responses to PAF in the airway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / blood
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / deficiency*
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / genetics
  • Administration, Inhalation
  • Adult
  • Alleles
  • Asthma / enzymology
  • Asthma / epidemiology
  • Bronchoconstriction / drug effects*
  • Bronchoconstriction / physiology*
  • Female
  • Heterozygote
  • Homozygote
  • Humans
  • Japan / epidemiology
  • Kinetics
  • Lymphocytes / drug effects
  • Lymphocytes / metabolism
  • Male
  • Neutropenia / chemically induced
  • Neutropenia / metabolism
  • Platelet Activating Factor / administration & dosage
  • Platelet Activating Factor / adverse effects*
  • Respiratory Function Tests / methods

Substances

  • Platelet Activating Factor
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase